tiprankstipranks
Neurogene (NGNE)
NASDAQ:NGNE
US Market
NGNE
Neurogene
RESEARCH TOOLSreports
Want to see NGNE full AI Analyst Report?

Neurogene (NGNE) Stock Forecast & Price Target

647 Followers
See the Price Targets and Ratings of:

NGNE Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Neurogene
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NGNE Stock 12 Month Forecast

Average Price Target

$81.83
▲(100.38% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Neurogene in the last 3 months. The average price target is $81.83 with a high forecast of $166.00 and a low forecast of $46.00. The average price target represents a 100.38% change from the last price of $40.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","167":"$167","53.75":"$53.8","91.5":"$91.5","129.25":"$129.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$166.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.83333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,53.75,91.5,129.25,167],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.89,43.12923076923077,53.368461538461546,63.60769230769231,73.84692307692308,84.08615384615385,94.32538461538462,104.5646153846154,114.80384615384617,125.04307692307694,135.2823076923077,145.52153846153848,155.76076923076926,{"y":166,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.89,36.654871794871795,40.41974358974359,44.184615384615384,47.94948717948718,51.71435897435897,55.47923076923077,59.24410256410256,63.008974358974356,66.77384615384615,70.53871794871795,74.30358974358974,78.06846153846153,{"y":81.83333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.89,33.89846153846154,34.90692307692308,35.91538461538462,36.923846153846156,37.932307692307695,38.940769230769234,39.949230769230766,40.95769230769231,41.966153846153844,42.97461538461539,43.98307692307692,44.99153846153846,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.33,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$166.00Average Price Target$81.83Lowest Price Target$46.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on NGNE
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
12.63%
Upside
Reiterated
08/13/26
Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)
Canaccord Genuity Analyst forecast on NGNE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$180→$166
Buy
306.46%
Upside
Reiterated
08/12/26
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166
H.C. Wainwright Analyst forecast on NGNE
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$70→$65
Buy
59.16%
Upside
Reiterated
08/12/26
Neurogene Buy Rating Reaffirmed as NGN-401 Progresses; 12‑Month Price Target Trimmed from $70 to $65 on Model Updates and Financing Dilution
TD Cowen Analyst forecast on NGNE
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on NGNE
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE) and Cardiff Oncology (NASDAQ: CRDF)
Guggenheim Analyst forecast on NGNE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$69→$81
Buy
98.33%
Upside
Reiterated
08/11/26
Guggenheim Sticks to Their Buy Rating for Neurogene (NGNE)
LifeSci Capital Analyst forecast on NGNE
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$65→$63
Buy
54.26%
Upside
Reiterated
08/11/26
Analyst Maintains Buy on NGN-401 After Strong Rett Data and Cleared Safety Window, Trims Price Target to $63
Rodman & Renshaw Analyst forecast on NGNE
Seema Sheoran
Rodman & Renshaw
Rodman & Renshaw
$70
Buy
71.40%
Upside
Initiated
06/03/26
Neurogene initiated with a Buy at Rodman & RenshawNeurogene initiated with a Buy at Rodman & Renshaw
Craig-Hallum Analyst forecast on NGNE
Albert Lowe
Craig-Hallum
Craig-Hallum
$65
Buy
59.16%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: RenovoRx (NASDAQ: RNXT), Neurogene (NASDAQ: NGNE) and ARS Pharmaceuticals (NASDAQ: SPRY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on NGNE
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$46
Buy
12.63%
Upside
Reiterated
08/13/26
Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)
Canaccord Genuity Analyst forecast on NGNE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$180→$166
Buy
306.46%
Upside
Reiterated
08/12/26
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166
H.C. Wainwright Analyst forecast on NGNE
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$70→$65
Buy
59.16%
Upside
Reiterated
08/12/26
Neurogene Buy Rating Reaffirmed as NGN-401 Progresses; 12‑Month Price Target Trimmed from $70 to $65 on Model Updates and Financing Dilution
TD Cowen Analyst forecast on NGNE
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on NGNE
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE) and Cardiff Oncology (NASDAQ: CRDF)
Guggenheim Analyst forecast on NGNE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$69→$81
Buy
98.33%
Upside
Reiterated
08/11/26
Guggenheim Sticks to Their Buy Rating for Neurogene (NGNE)
LifeSci Capital Analyst forecast on NGNE
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$65→$63
Buy
54.26%
Upside
Reiterated
08/11/26
Analyst Maintains Buy on NGN-401 After Strong Rett Data and Cleared Safety Window, Trims Price Target to $63
Rodman & Renshaw Analyst forecast on NGNE
Seema Sheoran
Rodman & Renshaw
Rodman & Renshaw
$70
Buy
71.40%
Upside
Initiated
06/03/26
Neurogene initiated with a Buy at Rodman & RenshawNeurogene initiated with a Buy at Rodman & Renshaw
Craig-Hallum Analyst forecast on NGNE
Albert Lowe
Craig-Hallum
Craig-Hallum
$65
Buy
59.16%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: RenovoRx (NASDAQ: RNXT), Neurogene (NASDAQ: NGNE) and ARS Pharmaceuticals (NASDAQ: SPRY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurogene

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
13/18 ratings generated profit
72%
Average Return
+17.61%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +17.61% per trade.
1 Year
Paul MatteisStifel Nicolaus
Success Rate
11/14 ratings generated profit
79%
Average Return
+32.28%
Copying Paul Matteis's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +32.28% per trade.
2 Years
Paul MatteisStifel Nicolaus
Success Rate
12/14 ratings generated profit
86%
Average Return
+58.51%
Copying Paul Matteis's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +58.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NGNE Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
14
19
17
15
Buy
4
7
6
6
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
21
25
23
21
In the current month, NGNE has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NGNE average Analyst price target in the past 3 months is 81.83.
Each month's total comprises the sum of three months' worth of ratings.

NGNE Financial Forecast

NGNE Earnings Forecast

Next quarter’s earnings estimate for NGNE is -$1.33 with a range of -$1.57 to -$0.96. The previous quarter’s EPS was -$1.53. NGNE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NGNE has Performed in-line its overall industry.
Next quarter’s earnings estimate for NGNE is -$1.33 with a range of -$1.57 to -$0.96. The previous quarter’s EPS was -$1.53. NGNE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NGNE has Performed in-line its overall industry.

NGNE Sales Forecast

Next quarter’s sales forecast for NGNE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NGNE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NGNE has Performed in-line its overall industry.
Next quarter’s sales forecast for NGNE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NGNE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NGNE has Performed in-line its overall industry.

NGNE Stock Forecast FAQ

What is NGNE’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurogene’s 12-month average price target is 81.83.
    What is NGNE’s upside potential, based on the analysts’ average price target?
    Neurogene has 100.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NGNE a Buy, Sell or Hold?
          Neurogene has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Neurogene’s price target?
            The average price target for Neurogene is 81.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $166.00 ,the lowest forecast is $46.00. The average price target represents 100.38% Increase from the current price of $40.84.
              What do analysts say about Neurogene?
              Neurogene’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of NGNE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.